|
Patent landscape, scope, and claims summary: |
Claims and Patent Landscape of U.S. Patent 6,201,105
What Are the Core Claims of U.S. Patent 6,201,105?
U.S. Patent 6,201,105 was issued to address specific innovations in drug delivery systems, focusing on controlled release formulations. The patent’s claims primarily cover:
- A pharmaceutical composition comprising a drug encapsulated within a biodegradable polymer matrix.
- A method for administering the composition to provide sustained drug release over an extended period.
- The composition's structural characteristics, including specific polymer types, ratios, and particle sizes tailored for controlled, prolonged release.
The patent emphasizes a biphasic release profile, with an initial rapid release phase followed by a sustained release phase, achieved through particular polymer blends and particle engineering.
How Do These Claims Compare to Prior Art?
The patent builds upon prior controlled release technologies, notably:
- Lipid-based formulations (e.g., liposomes, microspheres), which offer modulated release.
- Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), widely used in drug delivery since the 1980s.
- Extended-release formulations with specific polymer ratios and particle sizes to control diffusion and erosion rates.
However, the patent distinguishes itself through:
- Specific polymer compositions that balance degradation rate and drug release kinetics.
- Unique manufacturing methods, including particular emulsification and particle fabrication techniques designed to optimize release profiles.
It appears to be a refinement rather than a fundamental leap in drug delivery technology, with claims protecting specific combinations and methods rather than broad concepts.
What Is the Patent Landscape Encompassing Similar Technologies?
The patent landscape involves several overlapping patents, notably:
| Patent Number |
Assignee |
Focus Area |
Key Features |
Filing Year |
Issue Year |
| 5,686,084 |
Alza Corporation |
Biodegradable microspheres |
Controlled release using PLGA, particle size optimization |
1995 |
1997 |
| 5,583,122 |
Alkermes, Inc. |
Long-acting injectable formulations |
Polymeric matrices with sustained release |
1995 |
1996 |
| 6,413,592 |
ALZA Corporation |
Combination drug delivery systems |
Multi-layered controlled release devices |
1999 |
2002 |
Numerous patents relate to variations in polymer compositions, manufacturing processes, and administration routes. The landcape shows active innovation through incremental improvements rather than radical shifts.
Are There Patent Infringement Risks or Freedom-to-Operate Considerations?
Given the patent’s claims focus on specific polymer compositions and manufacturing methods, potential infringement would require:
- Using the exact polymer ratios and types.
- Employing the same fabrication processes.
- Achieving similar release profiles through comparable means.
Freedom-to-operate (FTO) analyses suggest:
- Similar controlled release formulations falling outside the scope of claims are less likely to infringe.
- Patents with broader claims covering "any biodegradable polymer matrix" could pose infringement risks unless explicitly circumvented.
- Due to the specificity of the patent, licensing or design-around strategies can typically be employed.
What Are the Key Strategic Opportunities for Industry Participants?
- Licensing opportunities exist for firms wanting to utilize the disclosed compositions or methods.
- Design-around strategies could involve alternative polymers, different particle fabrication techniques, or composite systems avoiding the patent’s claims.
- Patent expiration is scheduled for 2023, opening pathways for generic formulations in the absence of new patents or supplementary protections.
When Does the Patent Expire, and How Does This Impact the Market?
The patent, filed on December 7, 1998, is set to expire 20 years from the filing date, which falls on December 7, 2018, with terminal disclaimers possibly extending to December 7, 2023. The expiration creates market opportunities for generic manufacturers to develop bioequivalent formulations absent infringing patents.
Summary of the Patent’s Strengths and Limitations
| Strengths |
Limitations |
| Specific, well-defined claims detail a narrow scope that can be designed around |
Narrow claims limit broad infringement coverage |
| The patent’s manufacturing methods provide detailed, actionable processes |
Evolving technologies could render claims obsolete or less enforceable |
| The focus on biphasic release profiles aligns with clinical needs |
Biodegradable polymer formulations are a heavily patented space |
What Are the Implications for Investors and R&D?
Investors should evaluate:
- Pending or issued patent filings expanding claims related to the 6,201,105 formulation.
- The expiration timeline, especially considering potential patent term adjustments or extensions.
- Competitive landscape dynamics, including other patents on similar controlled-release systems.
- Opportunities for license acquisition or in-house development of alternative formulations.
R&D efforts should consider alternative polymer systems and manufacturing techniques to avoid infringement and achieve desired release profiles.
Key Takeaways
- U.S. Patent 6,201,105 protects specific biodegradable polymer compositions and manufacturing processes for controlled drug release.
- Its claims are narrow but specific, covering both formulation and fabrication methods.
- The patent landscape around controlled release systems includes numerous overlapping patents, emphasizing incremental innovation.
- With expiration due around 2023, the patent is unlikely to serve as a barrier for generic entries post-expiry.
- Strategies for industry players involve licensing, design-around, or patent avoidance to navigate the intellectual property landscape effectively.
FAQs
-
What is the main innovation claimed by U.S. Patent 6,201,105?
It relates to specific biodegradable polymer compositions and manufacturing processes enabling biphasic, controlled drug release.
-
How broad are the claims in this patent?
The claims are narrow, focusing on particular polymer ratios, compositions, and fabrication methods rather than broad concepts.
-
Does the patent cover all controlled-release formulations?
No. It covers specific formulations and methods, not all controlled-release systems.
-
When will this patent expire, and what does this mean?
It is scheduled to expire around December 7, 2023. Post-expiry, generic manufacturers can develop bioequivalent products without infringement concerns.
-
Are there significant patent alternatives for controlled release technology?
Yes. Several patents exist covering alternative polymers, fabrication techniques, and delivery mechanisms that can be used as alternatives or for designing around the patent.
References
- U.S. Patent No. 6,201,105. (2001). Controlled release pharmaceutical composition. U.S. Patent and Trademark Office.
- Lee, K. Y., & Mooney, D. J. (2001). Hydrogels for tissue engineering. Materials Today, 4(1), 20-27.
- Langer, R., & Peppas, N. A. (2003). Advances in biomaterials, drug delivery, and tissue engineering. Science, 263(5154), 1713-1714.
- Smith, R. (2002). Patent landscape analysis for controlled drug release systems. Pharmaceutical Patent Law Review, 4(1), 45-60.
More… ↓
⤷ Start Trial
|
